Novozymes A/S (OTCMKTS:NVZMY) Short Interest Update

Novozymes A/S (OTCMKTS:NVZMY) was the recipient of a large growth in short interest in the month of May. As of May 15th, there was short interest totaling 30,830 shares, a growth of 253.0% from the April 30th total of 8,733 shares. Approximately 0.0% of the company’s shares are short sold. Based on an average trading volume of 92,688 shares, the short-interest ratio is currently 0.3 days.

Novozymes A/S Trading Down 2.4%

Shares of NVZMY traded down $1.41 during mid-day trading on Friday, reaching $57.61. The company had a trading volume of 29,327 shares, compared to its average volume of 88,964. The stock has a market cap of $23.88 billion, a price-to-earnings ratio of 38.93, a price-to-earnings-growth ratio of 1.10 and a beta of 0.98. The firm has a fifty day simple moving average of $59.08 and a 200-day simple moving average of $60.81. Novozymes A/S has a fifty-two week low of $49.90 and a fifty-two week high of $75.99. The company has a current ratio of 0.72, a quick ratio of 0.44 and a debt-to-equity ratio of 0.12.

Novozymes A/S (OTCMKTS:NVZMY) last announced its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.51 earnings per share for the quarter, missing analysts’ consensus estimates of $0.82 by ($0.31). The company had revenue of $1.31 billion during the quarter, compared to analyst estimates of $1.32 billion. Novozymes A/S had a net margin of 14.22% and a return on equity of 6.57%. On average, sell-side analysts anticipate that Novozymes A/S will post 2.43 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have commented on NVZMY shares. Zacks Research cut shares of Novozymes A/S from a “hold” rating to a “strong sell” rating in a research note on Monday, May 4th. Kepler Capital Markets raised shares of Novozymes A/S from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, May 13th. Finally, Rothschild & Co Redburn raised shares of Novozymes A/S to a “strong-buy” rating in a research note on Friday, March 27th. Two investment analysts have rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy”.

Novozymes A/S Company Profile

Novozymes A/S is a Danish biotechnology company that develops, produces and markets industrial enzymes and microorganisms. Headquartered in Bagsværd, Denmark, the company focuses on using biological solutions to improve industrial processes across a range of end markets. Its offerings are designed to increase product performance or process efficiency while reducing energy, water and chemical consumption for customers.

The company’s product portfolio includes enzymes and microbial solutions for household care (detergents and cleaning products), food and beverages (baking, brewing and dairy applications), bioenergy (enzymes for biofuel production), agriculture (microbial crop inputs and biocontrols) and industrial processing (textiles, pulp and paper, and wastewater treatment).